<< Bapineuzumab - Does anyone care to comment...........>>
Don't know exactly what comment you are seeking.
4 trials each appox 1000 patients. First 2 trials in US originally run by WYE, now JNJ, separated by APO class (carriers vs Non-carriers). Last two trials run by PFE in ROW.
The carrier trial was completed last month. This trial had a lower expected chance of success based on Phase 2 results and disease load. The non-carrier trial is expected to complete in August of this year. PFE trials expected read out in 2014.
JNJ has repeatedly said that they would report the results of BOTH trials together when completed. There are also phase 2 subq.
and vaccine phase 2 trials ongoing.
High risk and high reward. We know that drug is biological active in humans. In phase 2 PET scans, it does what it was designed to do (remove amyloid). And the multibillion dollar questions are:
1. Does removing amyloid have a positive disease modifying effect?
2. Assuming #1 is yes, how early must you treat in order to prove the effect ?